Trials / Recruiting
RecruitingNCT07002320
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
ASpiRE: A Proof-of-mechanism and Proof-of-concept Clinical Trial Evaluating the Safety, Tolerability, Biological and Anti-tumour Activity of Apalutamide With Dual CXCR1 and CXCR2 Blockade by SX-682 for Men Suffering From Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Institute of Cancer Research, United Kingdom · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SX-682 | SX-682 is supplied as 100mg film coated tablets. |
| DRUG | Apalutamide | Apalutamide is supplied as 60mg film coated tablets. |
Timeline
- Start date
- 2025-04-28
- Primary completion
- 2029-10-01
- Completion
- 2029-10-01
- First posted
- 2025-06-03
- Last updated
- 2026-04-15
Locations
4 sites across 2 countries: Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT07002320. Inclusion in this directory is not an endorsement.